administration for respiratory conditions such as asthma, COPD, cystic fibrosis, and pulmonary infections. It offers the advantage of direct drug delivery to the lungs with rapid onset and minimal systemic exposure. However, conducting Phase 1 clinical trials for inhaled therapies requires careful planning due to challenges in dose consistency, device handling, and measurement of pulmonary pharmacokinetics (PK) and pharmacodynamics (PD). This article walks through critical design considerations, device integration, and regulatory requirements for inhaled drug development.

Why Inhaled Therapies Require Special Consideration in Phase 1

• Localized delivery: PK/PD effects are regional and not fully reflected in plasma
• Device handling variability: Affects dose delivery and deposition
• Non-traditional biomarkers: Requires novel endpoints for lung-specific effects
• Complex formulations: May include dry powders, suspensions, or nebulized agents

Key Objectives in Phase 1 Inhalation Trials

• Evaluate safety and tolerability of the inhaled agent
• Characterize systemic and pulmonary PK
• Measure PD biomarkers (e.g., FeNO, FEV1, cytokine levels)
• Assess device usability and administration consistency

Study Design Considerations

1. Device Training and Compliance

• Subjects must be trained in correct inhalation technique
• Device actuation monitored by dose counters or video recording

2. Dosing Regimens

• Single ascending dose (SAD) and multiple ascending dose (MAD)
• Fixed inhalation time, tidal breathing vs. deep inhalation

3. Population Selection

• Often starts with healthy volunteers, except for irritant or cytotoxic agents
• Early patient cohorts may be used for severe respiratory indications

4. Inhaled Dose Estimation

• Delivered dose estimated using in vitro cascade impaction or exhaled drug collection
• Important for accurate PK modeling

PK and PD Measurement

1. Systemic PK

• Measured from plasma to evaluate absorption and clearance
• Typically lower than oral/IV drugs due to local deposition

2. Lung PK

• May require bronchoalveolar lavage (BAL) or induced sputum sampling
• Non-invasive imaging (e.g., gamma scintigraphy) used in some studies

3. PD Biomarkers

• FEV1, PEF, FVC, airway resistance
• FeNO for inflammation, cytokine levels in sputum or BAL
• Time-matched to PK sampling to observe PK/PD correlation

Devices in Early Development

• Metered Dose Inhalers (MDIs) – Pressurized with propellants
• Dry Powder Inhalers (DPIs) – Breath-actuated, flow-dependent delivery
• Nebulizers – Jet, mesh, or ultrasonic options for liquid formulations

Device Usability and Human Factors

• Document subject errors in device actuation or breath coordination
• Track dose wasted, residuals, and actuation time
• Perform device feedback surveys or usability testing

Regulatory Perspectives

FDA

• Requires device-drug combination documentation
• Encourages inclusion of systemic and pulmonary PK/PD data
• Advises pre-IND meeting if novel devices or delivery routes are used

EMA

• Demands demonstration of consistent deposition and patient handling
• Requires bridging studies if device is changed between Phase 1 and Phase 3

CDSCO

• Expects device details and administration protocol in clinical trial applications
• Requires demonstration of local tolerability and AV consent documentation

Common Pitfalls in Inhaled Therapy Trials

• Inconsistent inhalation technique affecting PK profiles
• Lack of validated PD biomarkers
• Device malfunctions or untracked actuation errors

Best Practices

• Standardize training and monitor inhalation in every dosing session
• Use exhaled CO2 or acoustic sensors to verify delivery
• Incorporate PD endpoints early (e.g., FeNO, FEV1)
• Predefine device metrics to track for regulatory submission